Skip to main content

CROSS-TALK ENTRE LOS ASTROCITOS HIPOTALAMICOS Y EL TEJIDO ADIPOSO PERIVASCULAR EN EL METABOLISMO ENERGETICO Y LA FUNCION CARDIOVASCULAR: IMPACTO DE MODIFICACIONES EN LA DIETA

BFU2017-82565-C2-1-R

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2017
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION PARA LA INVESTIGACION BIOMEDICA HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESUS

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Pregnancy-associated plasma protein (PAPP)-A2 in physiology and disease

  • Barrios, Vicente
  • Chowen, Julie A.
  • Martín Rivada, Álvaro
  • Guerra-Cantera, Santiago
  • Pozo-Román, Jesús
  • Yakar, Shoshana
  • Rosenfeld, Ron G.
  • Pérez Jurado, Luis Alberto
  • Suárez, Juan
  • Argente, Jesús
The growth hormone (GH)/insulin-like growth factor (IGF) axis plays fundamental roles during development, maturation, and aging. Members of this axis, composed of various ligands, receptors, and binding proteins, are regulated in a tissue- and time-specific manner that requires precise control that is not completely understood. Some of the most recent advances in understanding the implications of this axis in human growth are derived from the identifications of new mutations in the gene encoding the pregnancy-associated plasma protein PAPP-A2 protease that liberates IGFs from their carrier proteins in a selective manner to allow binding to the IGF receptor 1. The identification of three nonrelated families with mutations in the PAPP-A2 gene has shed light on how this protease affects human physiology. This review summarizes our understanding of the implications of PAPP-A2 in growth physiology, obtained from studies in genetically modified animal models and the PAPP-A2 deficient patients known to date., This research was funded by the Spanish Ministry of Science and Innovation with the help of European FEDER funding (FIS PI19/00166 and PI19/00343), Ministerio de Economía y Competitividad (BFU 2017-82565-C2-1-R) and the Network Center for Biomedical Research on Obesity and Nutrition (CIBEROBN) Instituto Carlos III. S.G.-C. was supported by CIBEROBN.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Amyloid-β1-40 differentially stimulates proliferation, activation of oxidative stress and inflammatory responses in male and female hippocampal astrocyte cultures

  • Lennol, Matthew P.
  • Canelles, Sandra
  • Guerra-Cantera, Santiago
  • Argente, Jesús
  • García-Segura, Luis M.
  • Ceballos, María L. de
  • Chowen, Julie A.
  • Frago, Laura M.
Alzheimer's disease (AD) is the most common form of dementia and has a higher incidence in women. The main component of the senile plaques characteristic of AD is amyloid-beta (Aβ), with surrounding astrocytes contributing to the degenerative process. We hypothesized that the sex difference in the incidence of AD could be partially due to differential astrocytic responses to Aβ. Thus, the effect of Aβ on cell viability, the inflammatory response, and oxidative status was studied in cultures of hippocampal astrocytes from male and female rats. Aβ increased astrocyte viability in both female and male cultures by activating proliferation and survival pathways. Pro-inflammatory and anti-inflammatory responses were induced in astrocytes from both sexes. Aβ did not affect endoplasmic reticulum stress although it induced oxidative stress in male and female astrocytes. Interestingly, male astrocytes had an increase in cell number and significantly lower cell death in response to Aβ. Conversely, astrocytes from females displayed a greater inflammatory response after the Aβ challenge. These results suggest that the inflammatory and oxidative environment induced by Aβ in female astrocytes may contribute to enhance the vulnerability to AD and warrants further studies to unveil the mechanisms underlying sex differences in astrocytic responses., This work was supported by grants from Ministerio de Ciencia e Innovación (BFU2014-51836-C2-2-R to JAC, BFU2014-51836-C2-1-R to LMGS and BFU2017-82565-C2-1-R to JAC and LMF) and Fondo de Investigación Sanitaria (Grant PI16/00485 to JA), co-funded by Euro-pean FEDER Program, and Centro de Investigación Biomédica en Red Fisiopatología de Obesidad y Nutrición (CIBEROBN) of the Instituto de Salud Carlos III.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Role of glial cells in the generation of sex differences in neurodegenerative diseases and brain aging

  • Chowen, Julie A.
  • García-Segura, Luis M.
Diseases and aging-associated alterations of the nervous system often show sex-specific characteristics. Glial cells play a major role in the endogenous homeostatic response of neural tissue, and sex differences in the glial transcriptome and function have been described. Therefore, the possible role of these cells in the generation of sex differences in pathological alterations of the nervous system is reviewed here. Studies have shown that glia react to pathological insults with sex-specific neuroprotective and regenerative effects. At least three factors determine this sex-specific response of glia: sex chromosome genes, gonadal hormones and neuroactive steroid hormone metabolites. The sex chromosome complement determines differences in the transcriptional responses in glia after brain injury, while gonadal hormones and their metabolites activate sex-specific neuroprotective mechanisms in these cells. Since the sex-specific neuroprotective and regenerative activity of glial cells causes sex differences in the pathological alterations of the nervous system, glia may represent a relevant target for sex-specific therapeutic interventions., We acknowledge support from CIBEROBN, CIBERFES, Fondo de Investigación Sanitaria (PI1900166), Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación (BFU2017-82565-C21-R2; BFU2017-82754-R) and Fondo Europeo de Desarrollo Regional (FEDER). Funding sources were not involved in any step of the design and preparation of this article, including the decision to submit it for publication.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Increased hypothalamic anti‐inflammatory mediators in non‐diabetic insulin receptor substrate 2‐deficient mice

  • Vinaixa, María
  • Canelles, Sandra
  • González-Murillo, África
  • Ferreira, Vítor
  • Grajales, Diana
  • Guerra-Cantera, Santiago
  • Campillo-Calatayud, Ana
  • Ramírez-Orellana, Manuel
  • Yanes, Óscar
  • Frago, Laura M.
  • Valverde, Ángela M.
  • Barrios, Vicente
© 2021 by the authors., Insulin receptor substrate (IRS) 2 is a key mediator of insulin signaling and IRS-2 knockout (IRS2−/−) mice are a preclinical model to study the development of diabetes, as they develop peripheral insulin resistance and beta-cell failure. The differential inflammatory profile and insulin signaling in the hypothalamus of non-diabetic (ND) and diabetic (D) IRS2−/− mice might be implicated in the onset of diabetes. Because the lipid profile is related to changes in inflammation and insulin sensitivity, we analyzed whether ND IRS2−/− mice presented a different hypothalamic fatty acid metabolism and lipid pattern than D IRS2−/− mice and the relationship with inflammation and markers of insulin sensitivity. ND IRS2−/− mice showed elevated hypothalamic anti-inflammatory cytokines, while D IRS2−/− mice displayed a proinflammatory profile. The increased activity of enzymes related to the pentose-phosphate route and lipid anabolism and elevated polyunsaturated fatty acid levels were found in the hypothalamus of ND IRS2−/− mice. Conversely, D IRS2−/− mice have no changes in fatty acid composition, but hypothalamic energy balance and markers related to anti-inflammatory and insulin-sensitizing properties were reduced. The data suggest that the concurrence of an anti-inflammatory profile, increased insulin sensitivity and polyunsaturated fatty acids content in the hypothalamus may slow down or delay the onset of diabetes., This work was supported by the Spanish Ministry of Science and Innovation with the help of European FEDER funding (grant numbers FIS PI19/00166, BFU 2017-82565-C2-1-R, and RTI2018-094052-B-100), Comunidad de Madrid, Spain (S2017/BMD-3684) and the Network Center for Biomedical Research on Obesity and Nutrition (CIBEROBN) and Diabetes (CIBERDEM) Instituto Carlos III. S.C. was supported by CIBEROBN and A.G.M. by Fundación para la Investigación Biomédica Hospital Infantil Universitario Niño Jesús.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Pregnancy-associated plasma protein (PAPP)-A2 in physiology and disease

  • Barrios, Vicente
  • Chowen, Julie A.
  • Martín Rivada, Álvaro
  • Guerra-Cantera, Santiago
  • Pozo-Román, Jesús
  • Yakar, Shoshana
  • Rosenfeld, Ron G.
  • Pérez Jurado, Luis Alberto
  • Suárez, Juan
  • Argente, Jesús
The growth hormone (GH)/insulin-like growth factor (IGF) axis plays fundamental roles during development, maturation, and aging. Members of this axis, composed of various ligands, receptors, and binding proteins, are regulated in a tissue- and time-specific manner that requires precise control that is not completely understood. Some of the most recent advances in understanding the implications of this axis in human growth are derived from the identifications of new mutations in the gene encoding the pregnancy-associated plasma protein PAPP-A2 protease that liberates IGFs from their carrier proteins in a selective manner to allow binding to the IGF receptor 1. The identification of three nonrelated families with mutations in the PAPP-A2 gene has shed light on how this protease affects human physiology. This review summarizes our understanding of the implications of PAPP-A2 in growth physiology, obtained from studies in genetically modified animal models and the PAPP-A2 deficient patients known to date., This research was funded by the Spanish Ministry of Science and Innovation with the help of European FEDER funding (FIS PI19/00166 and PI19/00343), Ministerio de Economía y Competitividad (BFU 2017-82565-C2-1-R) and the Network Center for Biomedical Research on Obesity and Nutrition (CIBEROBN) Instituto Carlos III. S.G.-C. was supported by CIBEROBN.